Zocilurtatug pelitecan - ZAI Lab
Alternative Names: ZL-1310Latest Information Update: 10 Jun 2025
At a glance
- Originator ZAI Lab
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Small cell lung cancer
Most Recent Events
- 02 Jun 2025 Updated efficacy and adverse event data from a phase Ia/Ib trial in Small-cell lung cancer released by ZAI Lab
- 19 May 2025 ZL 1310 receives Fast Track designation for Small cell lung cancer [IV] (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 19 May 2025 ZL 1310 receives Fast Track designation for Small cell lung cancer [IV] (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA